Erik R Dubberke MD
Assistant Professor, Internal Medicine, Washington University School of Medicine
Join to View Full Profile
620 S Taylor Ave# DvSaint Louis, MO 63110
Phone+1 314-362-9098
Fax+1 314-362-9851
Dr. Dubberke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 2002 - 2004- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2002
University of Illinois College of MedicineClass of 1999
Certifications & Licensure
MO State Medical License 2000 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Autologous Fecal Therapy Start of enrollment: 2014 Mar 01
- Fecal Microbiota Transplantation (FMT) for MDRO UTI Start of enrollment: 2018 Feb 08
- TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment Start of enrollment: 2017 Dec 29
- Join now to see all
Publications & Presentations
PubMed
- Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing RecurrentInfection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUN...Carolyn D Alonso, Glenn S Tillotson, Monique R Bidell, Beth Guthmueller, Frederikke Hoeyer
Open Forum Infectious Diseases. 2025-04-01 - 3 citationsPUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent C...Paul Feuerstadt, Teena Chopra, Whitfield Knapple, Nicholas W Van Hise, Erik R Dubberke
Clinical Infectious Diseases. 2025-02-05 - Commensal-pathogen dynamics structure disease outcomes during Clostridioides difficile colonization.Skye R S Fishbein, Anna L DeVeaux, Sakshi Khanna, Aura L Ferreiro, James Liao
Cell Host & Microbe. 2025-01-08
Press Mentions
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 13th, 2023
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial ResultsNovember 4th, 2019
Gut Makeup Could Make Diarrhea Less LikelyAugust 16th, 2019- Join now to see all
Grant Support
- High-resolution genomic interrogation of pathogen-microbiome interactions in Clostridioides difficile infectionWASHINGTON UNIVERSITY2024–2029
- C. Difficile Disease In Stem Cell Transplant RecipientsNational Institute Of Allergy And Infectious Diseases2009–2011
- Validation And Modeling Of A C. Difficile Infection Risk Prediction IndexNational Institute Of Nursing Research2009–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
